OPEN ACCESS
World Journal of Applied Medical Sciences
ISSN: 3049-0200 | Vol. 1, No. 2, 2024
Website: https://wasrpublication.com/wjams/

Exploring Phage Therapy as an Alternative to Antibiotics in Treating Multidrug-Resistant Bacterial Infections

Bernaitis L[1*], Nidhyashree V[2], Shri Shanmathi K[2], Dhana Packiya Lakshmi B[2], Dhanalakshmi M[2], Bharathipriya M[2]

[1]Associate professor, Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052.

[2]Under graduate, Nandha Siddha Medical College and Hospital, Erode-638052.

Received: 10/10/2024 | Accepted: 01/11/2024 | Published: 21/11/2024

Abstract: Multidrug-resistant (MDR) bacterial infections have become an escalating global health crisis, significantly limiting the effectiveness of antibiotics. With rising resistance rates, the need for alternative treatment strategies is more critical than ever. Phage therapy, which utilizes bacteriophages—viruses that specifically target and kill bacteria—has emerged as a promising alternative. Phages offer a highly specific mechanism of action and can be used synergistically with antibiotics to improve treatment efficacy. Advances in phage engineering, delivery methods, and their combination with antibiotics enhance their therapeutic potential, particularly against MDR pathogens. However, challenges such as phage resistance, regulatory barriers, and delivery efficiency remain. This review explores the mechanisms of phage action, clinical applications in MDR infections, and the future directions in phage therapy research.

Keywords: Multidrug-resistant bacteria, bacteriophage, phage therapy, antibiotic resistance, biofilms, alternative therapies.

Cite this article:

Bernaitis, L., Nidhyashree, V., Shanmathi, K., Dhana, P. L. B., Dhanalakshmi, M., Bharathipriya, M., (2024). Exploring Phage Therapy as an Alternative to Antibiotics in Treating Multidrug-Resistant Bacterial Infections. *World Journal of Applied Medical Sciences, 1*(2), 12-14.

1.0 Introduction

The rise of multidrug-resistant (MDR) bacterial infections poses a critical threat to global public health, challenging the effectiveness of existing antibiotics and leading to a growing number of untreatable infections. According to the World Health Organization (WHO), antimicrobial resistance is one of the top 10 global public health threats, with predictions that it could cause up to 10 million deaths annually by 2050 if not addressed(1). Traditional antibiotics, once hailed as miracle drugs, are losing their efficacy due to the misuse and overuse in human medicine, agriculture, and veterinary practices(2). This alarming scenario has catalyzed the search for alternative therapies that can combat resistant pathogens, one of which is phage therapy.

Phage therapy, which employs bacteriophages—viruses that specifically infect bacteria—has garnered increasing interest as a potential solution to antibiotic resistance(3). Bacteriophages, or phages, were first discovered in the early 20th century and were initially used to treat bacterial infections. However, with the advent of antibiotics, interest in phage therapy waned in much of the world, although it continued to be explored in Eastern Europe and the former Soviet Union(4). Unlike antibiotics, which target broad bacterial groups, phages are highly specific to their bacterial hosts, offering the advantage of targeting MDR bacteria without harming beneficial microorganisms in the human body(5).

Recent advances in molecular biology and microbiology have renewed the scientific community's interest in phage therapy. The ability to genetically engineer phages to enhance their efficacy and safety profiles makes them a promising tool in treating MDR infections. Phages can be isolated from natural environments, such as sewage and soil, where bacteria and phages co-evolve. This dynamic interaction offers a rich resource for discovering new phages capable of tackling resistant bacterial strains(6).

Phage therapy presents several advantages over traditional antibiotics, including its specificity, ability to evolve alongside bacteria, and the potential to disrupt biofilms—a common defense mechanism of MDR bacteria(7). Moreover, phages can be combined with existing antibiotics to enhance their effectiveness, a strategy that could delay the development of resistance and improve treatment outcomes(8).
This article aims to explore the potential of phage therapy as an alternative or complementary approach to antibiotics in combating multidrug-resistant bacterial infections. The review will examine the mechanisms of phage action, the current state of research on phage therapy, challenges in clinical implementation, and future directions for its development.

2.0 Overview of Multidrug-Resistant Bacterial Infections

Multidrug-resistant (MDR) bacterial infections pose a serious global threat, with bacteria developing resistance to multiple antibiotics, making infections harder to treat. This resistance has escalated due to overuse and misuse of antibiotics in clinical and agricultural settings. The World Health Organization (WHO) identifies pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA), Carbapenem-resistant Enterobacteriaceae, and Multidrug-resistant Pseudomonas aeruginosa as critical threats. Mechanisms of antibiotic resistance include the production of enzymes like beta-lactamases, modification of drug targets, and efflux pumps that expel antibiotics from bacterial cells (9). These challenges highlight the urgent need for alternative treatment options to combat MDR infections.

***Corresponding Author**
Bernaitis L *
Associate professor, Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052.

3.0 Introduction to Phage Therapy

Phage therapy, which utilizes bacteriophages (viruses that infect and kill bacteria), is a promising alternative to antibiotics. Phages were first discovered by Frederick Twort and Félix d'Herelle in the early 20th century. They were initially used to treat bacterial infections before the discovery of antibiotics. However, with the advent of antibiotics in the 1940s, phage therapy fell out of favor in Western medicine. In recent decades, the rise of MDR bacteria has sparked renewed interest in phage therapy. Phages have been used successfully in Eastern European countries such as Georgia and Poland for decades (10).

4.0 Mechanisms of Bacteriophage Action

Bacteriophages target bacteria through highly specific mechanisms, typically infecting only one strain or species. They attach to bacterial surface receptors, inject their genetic material, and replicate within the host, ultimately lysing the bacterial cell to release new phages. There are two types of phages: lytic and lysogenic. Lytic phages are preferred for therapeutic use because they immediately destroy their bacterial hosts, unlike lysogenic phages, which integrate their DNA into the bacterial genome and may contribute to horizontal gene transfer (11). Phages can also disrupt biofilms, a protective structure that bacteria form to resist antibiotics. This makes them highly effective against biofilm-associated infections (12).

5.0 Phage Therapy in Treating Multidrug-Resistant Infections

Phage therapy has shown promise in treating MDR bacterial infections, especially those caused by MRSA, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Clinical trials and case studies have reported successful outcomes in patients with chronic wounds, respiratory infections, and sepsis that were unresponsive to antibiotics (13). One notable case involved a patient with a drug-resistant Acinetobacter baumannii infection who recovered after phage therapy following a lung transplant (14). However, phage therapy is not without limitations, including narrow host ranges and the potential for bacterial resistance to phages.

6.0 Phage Therapy and Antibiotic Synergy

Combining phages with antibiotics can enhance treatment outcomes. Research has shown that phage-antibiotic combinations can act synergistically, reducing bacterial loads more effectively than either treatment alone. This combination can also help prevent the development of resistance to both antibiotics and phages (15). In biofilm-associated infections, the use of phages alongside antibiotics has proven particularly effective, as phages can degrade the biofilm matrix, allowing antibiotics to penetrate and kill the bacteria within (16). This strategy is especially useful against pathogens like Pseudomonas aeruginosa and Staphylococcus aureus.

7.0 Challenges and Limitations of Phage Therapy

Phage therapy faces several challenges. One major issue is the development of phage resistance in bacteria, which can occur through mutations in bacterial surface receptors. However, this resistance can sometimes make bacteria more susceptible to antibiotics (17). Another challenge is the lack of regulatory frameworks for phage therapy. Since phages are considered biological products, they require a different regulatory approach than traditional antibiotics. Additionally, phage stability can be an issue, as they may lose activity during storage or transport (18). Finally, immune responses to phages in patients can limit their effectiveness, although this is less of a concern with lytic phages.

8.0 Advances in Phage Engineering and Genetic Modification

Advances in genetic engineering have enabled the development of more effective phages. Genetically modified phages can be designed to overcome bacterial resistance or to carry additional antimicrobial payloads, such as enzymes that degrade biofilms or antibiotics (19). Phage cocktails, which contain multiple types of phages targeting different bacterial strains, are also being developed to broaden the spectrum of phage therapy (20). The use of CRISPR-Cas systems in phages is another exciting advancement, allowing for precise targeting and modification of bacterial genomes, further enhancing the therapeutic potential of phages (21).

9.0 Delivery Methods for Phage Therapy

The delivery of phages to infection sites is critical for the success of therapy. Phages can be administered through various routes, including oral, topical, and intravenous. Phage encapsulation technologies, such as using liposomes or polymeric nanoparticles, have been developed to protect phages from degradation in the body and to enhance their delivery to infection sites (22). The use of bacteriophage-loaded dressings has been explored for treating skin infections and wounds (23). Nanotechnology is also being investigated to improve phage delivery and stability in clinical settings (24).

10.0 Future Directions in Phage Therapy Research

The future of phage therapy lies in personalized medicine, where phages are matched to the specific bacterial strains infecting a patient. Advances in metagenomics and bacterial profiling will make this approach more feasible (25). Combining phage therapy with immunotherapy and other antimicrobial strategies is another promising direction. Additionally, ongoing research aims to integrate phage therapy with antibiotic stewardship programs to reduce antibiotic use and limit the spread of resistance (26). The use of phages in combination with other technologies, such as synthetic biology, could lead to the development of even more potent antimicrobial therapies.

11.0 Conclusion

Phage therapy offers a promising alternative to traditional antibiotics, particularly for the treatment of MDR infections. Although challenges remain, advances in genetic engineering, delivery methods, and regulatory frameworks are paving the way for wider clinical use of phages. Future research should focus on optimizing phage selection, addressing resistance mechanisms, and integrating phage therapy into mainstream medical practice.

References

1. World Health Organization. Antimicrobial resistance. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
2. Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J. A., Klugman, K., & Davies, S. (2016). Access to effective antimicrobials: a worldwide challenge. *The*

Lancet, *387*(10014), 168-175. doi:10.1016/S0140-6736(15)00474-2.

3. Chaudhari, N. M., Gautam, A., Gupta, V. K., Kaur, G., Dutta, C., & Paul, S. (2018). PanGFR-HM: a dynamic web resource for pan-genomic and functional profiling of human microbiome with comparative features. *Frontiers in microbiology*, *9*, 2322. doi:10.3389/fmicb.2018.02322.
4. Abedon, S. T., García, P., Mullany, P., & Aminov, R. (2017). Phage therapy: past, present and future. *Frontiers in microbiology*, *8*, 981. doi:10.3389/fmicb.2017.00981.
5. Górski A, Międzybrodzki R, Weber-Dąbrowska B, et al. (2019). Phage Therapy: Combating Infections with a Naturally Occurring Virus. Front Microbiol. 10:330. doi:10.3389/fmicb.2019.00330.
6. Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World journal of gastrointestinal pharmacology and therapeutics*, *8*(3), 162. doi:10.4292/wjgpt.v8.i3.162.
7. Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. *Future microbiology*, *8*(6), 769-783. doi:10.2217/fmb.13.47.
8. Nilsson, A. S. (2014). Phage therapy—constraints and possibilities. *Upsala journal of medical sciences*, *119*(2), 192-198. doi:10.3109/03009734.2014.896438.
9. Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiology and molecular biology reviews*, *74*(3), 417-433. doi:10.1128/MMBR.00016-10
10. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011). Phage treatment of human infections. *Bacteriophage*, *1*(2), 66-85. doi:10.4161/bact.1.2.15845
11. Labrie, S. J., Samson, J. E., & Moineau, S. (2010). Bacteriophage resistance mechanisms. *Nature Reviews Microbiology*, *8*(5), 317-327. doi:10.1038/nrmicro2315
12. Harper, D. R., Parracho, H. M., Walker, J., Sharp, R., Hughes, G., Werthén, M., ... & Morales, S. (2014). Bacteriophages and biofilms. *Antibiotics*, *3*(3), 270-284. doi:10.3390/antibiotics3030270
13. Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K., Harris, K., ... & Spencer, H. (2019). Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. *Nature medicine*, *25*(5), 730-733. doi:10.1038/s41591-019-0437-z
14. Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. *Future microbiology*, *8*(6), 769-783. doi:10.2217/fmb.13.47
15. Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World journal of gastrointestinal pharmacology and therapeutics*, *8*(3), 162. doi:10.4292/wjgpt.v8.i3.162
16. Oechslin, F. (2018). Resistance development to bacteriophages occurring during bacteriophage therapy. *Viruses*, *10*(7), 351. doi:10.3390/v10070351
17. Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019). Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. *Cell host & microbe*, *25*(2), 219-232. doi:10.1016/j.chom.2019.01.014